Abbott Laboratories
ABTNYSEHealthcare● Active
$91.07
+$0.29(+0.32%)
Market Cap$158.6B
P/E Ratio—
52W High$139.06
52W Low$81.97
Abbott Laboratories (ABT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ABT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B |
| Cost of Revenue | $19.72B | $20.63B | $20.07B | $21.33B | $19.86B |
| Gross Profit | $24.61B | $21.32B | $20.04B | $22.32B | $23.21B |
| Gross Margin %(computed) | 55.51% | 50.83% | 49.96% | 51.14% | 53.89% |
| Operating Expenses | |||||
| R&D Expenses | $2.96B | $2.82B | $2.72B | $2.85B | $2.74B |
| G&A Expenses | $12.38B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $16.59B | $14.47B | $13.60B | $13.96B | $14.01B |
| Operating Income | $8.05B | $6.83B | $6.43B | $8.36B | $9.20B |
| Operating Margin %(computed) | 18.16% | 16.27% | 16.04% | 19.16% | 21.36% |
| Interest Income | $0.23B | $0.34B | $0.39B | $0.18B | $0.04B |
| Interest Expense | $0.34B | $0.60B | $0.70B | $0.32B | $0.41B |
| Income Before Tax | $8.47B | $7.01B | $6.66B | $8.31B | $8.21B |
| Income Tax Expense | $1.94B | ($6.39B) | $0.94B | $1.37B | $1.14B |
| Net Income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| Net Margin %(computed) | 14.72% | 31.95% | 14.27% | 15.88% | 16.42% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.74 | $7.67 | $3.30 | $3.94 | $3.97 |
| Wtd Avg Shares | 1.75B | 1.73B | 1.73B | 1.75B | 1.77B |
| EBITDA | $11.55B | $10.83B | $10.61B | $11.89B | $12.16B |
| EBITDA Margin %(computed) | 26.06% | 25.83% | 26.44% | 27.23% | 28.23% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Abbott Laboratories data
About Abbott Laboratories (ABT) Income Statement
Abbott Laboratories (ABT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ABT reported revenue of $44.33B, gross profit of $24.61B (gross margin 55.51%), and net income of $6.52B — a net profit margin of 14.72%.
Frequently asked questions
ABT · 4 questionsAbbott Laboratories (ABT) reported revenue of $44.33B for 2025, up 5.7% year-over-year.
ABT revenueABT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08